Read by QxMD icon Read

ezetimibe diabetes

Peter P Toth, Alberico L Catapano, Michel Farnier, Joanne Foody, Joanne E Tomassini, Erin Jensen, Adam B Polis, Mary E Hanson, Thomas A Musliner, Andrew M Tershakovec
Statin therapy is associated with a slightly increased risk of developing diabetes mellitus and insulin resistance in patients without diabetes. Ezetimibe combined with statins may be considered for high-risk patients who do not achieve optimal low-density lipoprotein cholesterol lowering on statin monotherapy or who are statin intolerant. Changes in fasting serum glucose (FSG) levels during ezetimibe, ezetimibe/statin, and statin treatments were assessed using data pooled from clinical trials in hypercholesterolemic and heterozygous familial hypercholesterolemic patients, who were or were not receiving statin therapy...
September 13, 2016: American Journal of Cardiology
Peter H Jones, Harold E Bays, Umesh Chaudhari, Robert Pordy, Christelle Lorenzato, Kathryn Miller, Jennifer G Robinson
Previous individual trials of alirocumab (a PCSK9 monoclonal antibody) showed significant low-density lipoprotein cholesterol reductions with overall treatment-emergent adverse event (TEAE) rates comparable with controls. This analysis evaluated safety data from 14 trials (4 phase 2 and 10 phase 3, 8 to 104 weeks; n = 5,234), in 2 pools according to control (placebo/ezetimibe). Overall, 3,340 patients received alirocumab (4,029 patient-years' exposure), 1,276 received placebo, and 618 received ezetimibe. Incidence of deaths, serious TEAEs, discontinuations because of TEAEs, and overall TEAEs were similar between alirocumab and control groups...
September 14, 2016: American Journal of Cardiology
Mi Seon Ji, Myung Ho Jeong, Young Keun Ahn, Sang Hyung Kim, Young Jo Kim, Shung Chull Chae, Taek Jong Hong, In Whan Seong, Jei Keon Chae, Chong Jin Kim, Myeong Chan Cho, Seung-Woon Rha, Jang Ho Bae, Ki Bae Seung, Seung Jung Park
BACKGROUND: It is unclear whether simvastatin-ezetimibe could be an alternative therapy to high-intensity statin therapy in high-risk patients. The aim of this study was to compare the clinical outcomes of simvastatin-ezetimibe and high-intensity statin therapy in patients with acute myocardial infarction (AMI), and especially in those with high-risk factor. METHODS: A total of 3520 AMI patients in the KAMIR (Korea Acute Myocardial Infarction Registry) were classified into simvastatin-ezetimibe group (n=1249) and high-intensity statin group (n=2271)...
September 28, 2016: International Journal of Cardiology
Luca A Lotta, Stephen J Sharp, Stephen Burgess, John R B Perry, Isobel D Stewart, Sara M Willems, Jian'an Luan, Eva Ardanaz, Larraitz Arriola, Beverley Balkau, Heiner Boeing, Panos Deloukas, Nita G Forouhi, Paul W Franks, Sara Grioni, Rudolf Kaaks, Timothy J Key, Carmen Navarro, Peter M Nilsson, Kim Overvad, Domenico Palli, Salvatore Panico, Jose-Ramón Quirós, Elio Riboli, Olov Rolandsson, Carlotta Sacerdote, Elena Salamanca-Fernandez, Nadia Slimani, Annemieke M W Spijkerman, Anne Tjonneland, Rosario Tumino, Daphne L van der A, Yvonne T van der Schouw, Mark I McCarthy, Inês Barroso, Stephen O'Rahilly, David B Savage, Naveed Sattar, Claudia Langenberg, Robert A Scott, Nicholas J Wareham
Importance: Low-density lipoprotein cholesterol (LDL-C)-lowering alleles in or near NPC1L1 or HMGCR, encoding the respective molecular targets of ezetimibe and statins, have previously been used as proxies to study the efficacy of these lipid-lowering drugs. Alleles near HMGCR are associated with a higher risk of type 2 diabetes, similar to the increased incidence of new-onset diabetes associated with statin treatment in randomized clinical trials. It is unknown whether alleles near NPC1L1 are associated with the risk of type 2 diabetes...
October 4, 2016: JAMA: the Journal of the American Medical Association
Edith Heintjes, Josephina Kuiper, Bianca Lucius, Fernie Penning-van Beest, Lucie Kutikova, Anho Liem, Ron Herings
OBJECTIVE: To describe clinical characteristics and cholesterol management of patients with cardiovascular events (CVEs) and/or type 2 diabetes mellitus (T2DM) with high low-density lipoprotein cholesterol (LDL-C) > 1.8 mmol/L in the Netherlands. RESEARCH DESIGN AND METHODS: From the PHARMO Database Network a cross-sectional cohort was constructed. The descriptive study included patients on lipid modifying therapy (LMT) in 2009, classified as high cardiovascular risk based on a history of T2DM or CVE, with 2010 LDL-C levels above 1...
September 29, 2016: Current Medical Research and Opinion
Michal Vrablík
UNLABELLED: Dyslipidemia in type 2 diabetics represents a complex change of lipoprotein metabolism that is highly proatherogenic. It originates on a genetic background in the context of insulin resistance and affects lipoprotein metabolism at multiple levels (e.g. hepatocyte, enterocyte, intravascular processing) mainly in the postprandial phase. The treatment of diabetic (atherogenic) dyslipidemia is an effective option to lower the risk of both macro- and microvascular complications of diabetes...
2016: Vnitr̆ní Lékar̆ství
Peter Bramlage, Stefanie Lanzinger, Wolfgang Rathmann, Anton Gillessen, Nikolaus Scheper, Sebastian M Schmid, Matthias Kaltheuner, Jochen Seufert, Thomas Danne, Reinhard W Holl
AIMS: Dyslipidaemia is common in patients with type 2 diabetes mellitus (T2DM). Characterised by high levels of triglyceride (TG)-rich and small dense low-density lipoprotein particles, as well as low levels of high-density lipoprotein cholesterol (HDL-C), diabetic dyslipidaemia differs from non-diabetic individuals. Data regarding lipid abnormalities in T2DM patients, and the effect of treatment, are lacking. MATERIALS AND METHODS: We combined data from the German DIVE (DIabetes Versorgungs-Evaluation) and the DPV (Diabetes-Patienten-Verlaufsdokumentation) database to produce a large cohort of patients with T2DM...
September 4, 2016: Diabetes, Obesity & Metabolism
Rachel B Britt, Mohamed G Hashem, William E Bryan, Radhika Kothapalli, Jamie N Brown
BACKGROUND: Several cost analysis studies have been conducted looking at clinical and economic outcomes associated with clinical pharmacist services in a variety of health care settings. However, there is a paucity of data regarding the economic impact of clinical pharmacist involvement in formulary management at the hospital level. OBJECTIVE: To evaluate economic outcomes of a pharmacist-adjudicated formulary management consult service in a Veterans Affairs (VA) medical center offering outpatient and inpatient services...
September 2016: Journal of Managed Care & Specialty Pharmacy
Rachel B Britt, Mohamed G Hashem, William E Bryan, Radhika Kothapalli, Jamie N Brown
BACKGROUND: Several cost analysis studies have been conducted looking at clinical and economic outcomes associated with clinical pharmacist services in a variety of health care settings. However, there is a paucity of data regarding the economic impact of clinical pharmacist involvement in formulary management at the hospital level. OBJECTIVE: To evaluate economic outcomes of a pharmacist-adjudicated formulary management consult service in a Veterans Affairs (VA) medical center offering outpatient and inpatient services...
September 2016: Journal of Managed Care & Specialty Pharmacy
Kyung-Jin Kim, Sang-Hyun Kim, Young Won Yoon, Seung-Woon Rha, Soon-Jun Hong, Choong-Hwan Kwak, Weon Kim, Chang-Wook Nam, Moo-Yong Rhee, Tae-Ho Park, Taek-Jong Hong, Sungha Park, Youngkeun Ahn, Namho Lee, Hui-Kyung Jeon, Dong-Woon Jeon, Kyoo-Rok Han, Keon-Woong Moon, In-Ho Chae, Hyo-Soo Kim
AIM: We aimed to compare the effects of fixed-dose combinations of ezetimibe plus rosuvastatin to rosuvastatin alone in patients with primary hypercholesterolemia, including a subgroup analysis of patients with diabetes mellitus (DM) or metabolic syndrome (MetS). METHOD: This multicenter eight-week randomized double-blind phase III study evaluated the safety and efficacy of fixed-dose combinations of ezetimibe 10 mg plus rosuvastatin, compared with rosuvastatin alone in patients with primary hypercholesterolemia...
October 2016: Cardiovascular Therapeutics
Edda Bahlmann, Dana Cramariuc, Jan Minners, Mai Tone Lønnebakken, Simon Ray, Christa Gohlke-Baerwolf, Christoph A Nienaber, Nikolaus Jander, Reinhard Seifert, John B Chambers, Karl Heinz Kuck, Eva Gerdts
AIMS: In aortic valve stenosis (AS), having a small aortic root may influence both the assessment of AS severity and the treatment strategy. The aim was to test the prognostic implications of having a small aortic root in AS within a large prospective study. METHODS AND RESULTS: We used data from 4.3-year follow-up of 1560 patients with asymptomatic, initially mostly moderate AS enrolled in the Simvastatin and Ezetimibe in Aortic Stenosis study. A small aortic root was defined as inner aortic sinotubular junction diameter indexed for body height <1...
August 3, 2016: European Heart Journal Cardiovascular Imaging
Olav W Nielsen, Ahmad Sajadieh, Muhammad Sabbah, Anders M Greve, Michael H Olsen, Kurt Boman, Christoph A Nienaber, Y Antero Kesäniemi, Terje R Pedersen, Ronnie Willenheimer, Kristian Wachtell
BACKGROUND: Evidence for treating hypertension in patients with asymptomatic aortic valve stenosis is scarce. We used data from the SEAS trial (Simvastatin Ezetimibe in Aortic Stenosis) to assess what blood pressure (BP) would be optimal. METHODS: A total of 1767 patients with asymptomatic aortic stenosis and no manifest atherosclerotic disease were analyzed. Outcomes were all-cause mortality, cardiovascular death, heart failure, stroke, myocardial infarction, and aortic valve replacement...
August 9, 2016: Circulation
Helen M Colhoun, Henry N Ginsberg, Jennifer G Robinson, Lawrence A Leiter, Dirk Müller-Wieland, Robert R Henry, Bertrand Cariou, Marie T Baccara-Dinet, Robert Pordy, Laurence Merlet, Robert H Eckel
AIMS: Statins have modest adverse effects on glycaemic control. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers low-density lipoprotein cholesterol. This study assessed the effects of alirocumab on new-onset diabetes and pre-diabetes incidence in individuals without diabetes at baseline. METHODS AND RESULTS: Pooled analysis of 10 ODYSSEY Phase 3 trials (n = 4974) of 24-104 weeks duration. Six trials (n = 4211) were ≥52 weeks in length...
July 26, 2016: European Heart Journal
Xue Lin, RuiYi Xu, Ligang Fang, Wei Chen, Dayi Hu, Shuiping Zhao, Yongjun Wang, Jihu Li, Xiaowei Yan
BACKGROUND: Primary care facilities are the base for hypercholesterolemia treatment. However, data regarding the effectiveness of lipid management in primary care are lacking. METHODS AND RESULTS: To evaluate lipid management in the primary care setting in China, we compared patients' characteristics and lipid management outcomes between 6100 outpatients treated at primary care versus 19,217 patients in non-primary settings using data from the DYSlipidemia International Study-China (DYSIS-CHINA)...
November 1, 2016: International Journal of Cardiology
Georgina Del Vecchyo-Tenorio, Maricela Rodríguez-Cruz, Adolfo Andrade-Cetto, René Cárdenas-Vázquez
Creosote bush, Larrea tridentata (Sesse y Moc. Ex DC, Zygophyllaceae) is a shrub found in the deserts of Northern Mexico and Southwestern United States. In traditional medicine, it is used to treat a variety of illnesses including type 2 diabetes. The present study aims to investigate the effects of creosote bush ethanolic extract on plasma and liver parameters associated with the metabolic syndrome in hamsters fed a high fat and cholesterol diet (HFD), comparing them with those induced by ezetimibe (EZ). Seven groups of six hamsters each were formed...
2016: Frontiers in Pharmacology
Auryan Szalat, Ronen Durst, Eran Leitersdorf
Glucose-control has a modest beneficial effect on cardiovascular outcomes in patients with type 2 diabetes mellitus. Thus, managing other atherogenic risk factors including hypertriglyceridemia, low HDL-cholesterol and moderately elevated LDL-cholesterol levels with increased small dense LDL-cholesterol fraction, is crucial. Insulin resistance is a key pathophysiologic factor in this population. Treatment starts with lifestyle modifications, but current best programmes have not translated into positive cardiovascular outcomes...
June 2016: Best Practice & Research. Clinical Endocrinology & Metabolism
Barbara Nußbaumer, Anna Glechner, Angela Kaminski-Hartenthaler, Peter Mahlknecht, Gerald Gartlehner
BACKGROUND: To date, most clinical comparisons of ezetimibe-statin combination therapy versus statin monotherapy have relied entirely on surrogate variables. In this systematic review, we study the efficacy and safety of ezetimibe-statin combination therapy in comparison to statin monotherapy in terms of the prevention of cardiovascular events in hyperlipidemic patients with atherosclerosis and/or diabetes mellitus. METHODS: This review is based on a systematic literature search (1995 to July 2015) in PubMed, the Excerpta Medica Database (EMBASE), the Cochrane Library, and the ClinicalTrials...
July 1, 2016: Deutsches Ärzteblatt International
A K Gitt, R Zahn
Hypercholesterolemia is one of the major modifiable risk factors for the development of atherosclerosis. Increasing LDL cholesterol is associated with an increased risk of developing cardiovascular diseases as well as cardiovascular ischemic complications. Studies with statins and ultimately with ezetimibe have been able to impressively demonstrate that lowering LDL cholesterol contributes to a significant reduction of cardiovascular ischemic complications.Based on the results of randomized trials for lipid lowering, the practice guidelines developed by the professional societies have defined LDL cholesterol goals...
August 2016: Herz
Carlo Briguori, Rosalinda Madonna, Marco Zimarino, Paolo Calabrò, Cristina Quintavalle, Maria Salomone, Gerolama Condorelli, Raffaele De Caterina
BACKGROUND: Periprocedural myocardial infarction (MI) is a frequent complication of percutaneous coronary intervention (PCI). Statins might reduce its incidence. The aims of the present study are to assess whether such benefit is a class-effect or whether differences exist between various lipid-lowering strategies and whether cardioprotection is exerted by increasing circulating endothelial progenitor cells (EPCs). METHODS: The REMEDY study will enroll a total of 1080 patients submitted to elective PCI...
June 29, 2016: Cardiovascular Drugs and Therapy
Claudio Cimminiello, Alberto Zambon, Hernan Polo Friz
Cardiovascular disease is the leading cause of premature death in Europe. High blood cholesterol is one of the major cardiovascular risk factors and plays a crucial role in causing cardiovascular disease. A strong positive and linear association between total and LDL cholesterol levels and the risk of cardiovascular events has been widely documented. Every 1.0 mmol/l decrease in LDL cholesterol levels results in a significant reduction in cardiovascular mortality and in the risk of nonfatal myocardial infarction...
April 2016: Giornale Italiano di Cardiologia
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"